Aardvark Therapeutics vs Belite Bio
AARD and BLTE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AARD and BLTE compare
Aardvark Therapeutics scores higher on the StockData Score (6 against 5 for Belite Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AARD | BLTE |
|---|---|---|
| Size and price | ||
| Market cap | $33.3M | – |
| Share price | $1.52 | $169.96 |
| Change, 1 year | −86.3% | 60.7% |
| Beta (5Y) | 2.77 | 0.19 |
| Employees | 40 | 500 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× | – |
| Profitability | ||
| Return on equity | −66.0% | −16.9% (better) |
| Return on invested capital | – | −25.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −42104.0× |
| Current ratio | 12.63 | 50.02 (better) |
| Altman Z-score | −1.52 | – |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 43.6% | 24.1% |
| Held by insiders | 41.9% | 47.3% |
| Insider net buying, 12 months | −$250K (better) | −$40.6M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.2% | – |
Go deeper
- AARD stock overview
- AARD income statement
- AARD valuation and score
- BLTE stock overview
- BLTE income statement
- BLTE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.